Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Dec 3;16(12):e0261022.
doi: 10.1371/journal.pone.0261022. eCollection 2021.

The extent to which off-patent registered prescription medicines are used for off-label indications in Australia: A scoping review

Katrina Howe  1 , Siobhan Bourke  1 , Lloyd Sansom  2
Affiliations

The extent to which off-patent registered prescription medicines are used for off-label indications in Australia: A scoping review

Katrina Howe et al. PLoS One. .

Abstract

Aim: The aim of this scoping review was to determine the extent of off-patent prescription medicine use beyond registered indications in various Australian clinical settings.

Method: The review followed the Joanna Briggs Institute approach and reported using PRISMA Extension for Scoping Reviews. Online databases were used to identify published literature about off-patent registered prescription medicines used for off-label indications in Australian public hospital, community and primary healthcare settings. In addition, empirical data from the Queensland and the South Australian state-wide medicine formularies were screened for the same medication/off-label indication dyads identified in the literature, and other locally approved uses.

Results: Overall, fourteen studies were included, conducted in public hospitals (n = 11), palliative care units (n = 2) and the community setting (n = 1). There were 213 reports extracted from the literature describing off-patent registered prescription medicines used for off-label indications, representing 128 unique medication/off-label indication dyads and 32 different medicines. Of these, just five medication/off-label indication dyads were approved for use on both the Queensland and South Australian state-wide medicine formularies, with 12 others only approved for use in Queensland and 16 others only approved for use in South Australia. Further examination of these state-wide formularies demonstrated that the use of off-patent registered prescription medicines beyond registered indications is more extensive than has been reported to date in the literature. There were 28 additional medication/off-label indication dyads approved on the Queensland state-wide medicine formulary and 14 such examples approved for use in South Australia. Of these, just two medication/off-label indication dyads were approved for use on both formularies.

Conclusion: The extent to which off-patent registered prescription medicines have been repurposed in clinical settings for off-label indications in Australia is greater than previously reported in the literature. Usage and funded availability of certain medication/off-label indication dyads, varies across Australia. These results further expose the two tiered system of medicines regulation in Australia, and its impact on equity of access to medicines. Further research is required to support policy change to encourage submission of registration updates for off-patent prescription medicines.

PubMed Disclaimer

Conflict of interest statement

KH and LS are employed by the Australian Government Department of Health. The views expressed in this paper do not represent those of the Australian Government Department of Health. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. This does not alter our adherence to PLOS ONE policies on sharing data and materials.

Figures

Fig 1
Fig 1. Study flow diagram.
See this image and copyright information in PMC

References

    1. Langedijk J, Mantel-Teeuwisse A, Slijkerman D, Schutjens M. Drug repositioning and repurposing: terminology and definitions in literature. Drug Discovery Today. 2015;20(8):1027–34. doi: 10.1016/j.drudis.2015.05.001 - DOI - PubMed
    1. Murteira S, Ghezaiel Z, Karray S, Lamure M. Drug reformulations and repositioning in pharmaceutical industry and its impact on market access: reassessment of nomenclature. Journal of Market Access & Health Policy. 2013;1(1):21131. doi: 10.3402/jmahp.v1i0.21131 - DOI - PMC - PubMed
    1. Australian Government Department of Health. Australian regulation of prescription medical products 2020 Available from: https://www.tga.gov.au/australian-regulation-prescription-medical-products.
    1. Seale JP. Off-label prescribing. Medical Journal of Australia. 2014;200(2):65. doi: 10.5694/mja13.00184 - DOI - PubMed
    1. Gazarian M, Kelly M, McPhee JR, Graudins LV, Ward RL, Campbell TJ. Off‐label use of medicines: consensus recommendations for evaluating appropriateness. Medical Journal of Australia. 2006;185(10):544–8. doi: 10.5694/j.1326-5377.2006.tb00689.x - DOI - PubMed

Publication types

MeSH terms

Substances